千金药业(600479.SH)及子公司获得药品注册证书

Core Viewpoint - Qianjin Pharmaceutical (600479.SH) and its subsidiary Hunan Qianjin Xiangjiang Pharmaceutical Co., Ltd. have received drug registration certificates from the National Medical Products Administration for Dydrogesterone tablets, Baricitinib tablets (4mg, 2mg), and Dapagliflozin tablets (5mg, 10mg) [1] Group 1: Drug Approvals - The company has obtained approval for Dydrogesterone, a synthetic progestogen used for treating diseases caused by endogenous progesterone deficiency and for luteal support in assisted reproductive technology [1] - Baricitinib is a Janus kinase (JAK) inhibitor that blocks the activity of one or more members of the JAK kinase family, thereby inhibiting pathways that activate inflammation, developed in collaboration with Eli Lilly and Incyte [1] - Dapagliflozin is indicated for the treatment of type 2 diabetes [1]